Markets

Spectrum Pharmaceuticals (SPPI) Jumps: Stock Rises 7%

Spectrum Pharmaceuticals, Inc. SPPI was a big mover last session, as the company saw its shares rise 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $3.71 –$4.58 in the past one-month time frame, witnessed a sharp increase on Friday.

The company has seen one negative estimate revisions in the past few months, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few months, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Spectrum Pharmaceuticals currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%. 

Spectrum Pharmaceuticals, Inc. Price

Spectrum Pharmaceuticals, Inc. Price

Spectrum Pharmaceuticals, Inc. price | Spectrum Pharmaceuticals, Inc. Quote

A better-ranked stock in the Medical - Drugs industry is Catalent, Inc CTLT, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Zacks’ Single Best Pick to Double

From thousands of stocks, 5 Zacks experts each picked their favorite to gain +100% or more in months to come. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.

With users in 180 countries and soaring revenues, it’s set to thrive on remote working long after the pandemic ends. No wonder it recently offered a stunning $600 million stock buy-back plan.

The sky’s the limit for this emerging tech giant. And the earlier you get in, the greater your potential gain.

Click Here, See It Free >>


Click to get this free report

Spectrum Pharmaceuticals, Inc. (SPPI): Free Stock Analysis Report

Catalent, Inc. (CTLT): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More